Table 2.

Outcomes of the EMPOWER intervention by cognitive status

Primary outcome	All (n = 261) (n, %)	MCI (n = 122) (n, %)	Normal cognition (n = 139) (n, %)	Univariable OR (95% CI)	Multivariable OR (95% CI)a
Cessation	92 (35.2)	39 (32.0)	53 (38.1)	0.76 [.46–1.27]	.79 [.45–1.38]
Dose Reduction	28 (10.7)	16 (13.1)	12 (8.6)	1.60 [.72–3.53]	2.04 [.86–4.83]
Cessation + Dose Reduction	120 (45.9)	55 (45.1)	65 (46.8)	.94 [.57–1.52]	1.07 [.62–1.83]
Process Outcomes
Improvement in knowledge	157 (60.2)	75 (61.5)	82 (59.0)	1.11 [.68–1.82]	1.06 [.62–1.80]
Change in beliefs	147 (56.3)	67 (54.9)	80 (57.6)	.89 [.54–1.47]	.84 [.48–1.43]
Improved self-efficacy for tapering	144 (55.2)	68 (55.7)	76 (54.7)	1.04 [.64–1.70]	.89 [.52–1.54]
Discussed intervention with a physician	102 (39.1)	43 (35.2)	59 (42.6)	.73 [.44–1.22]	.75 [.43–1.32]
Discussed intervention with a pharmacist	55 (21.1)	26 (21.3)	29 (20.8)	1.02 [.57–1.86]	.89 [.46–1.72]
Experienced withdrawal symptoms during cessation	31 (11.9)	12 (9.8)	19 (13.7)	.69 [.32–1.49]	.60 [.27–1.35]

^aAnalyses adjusted for living arrangement, education, anxiety as an indication for benzodiazepine treatment and baseline self-efficacy